Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Marie C. Kyrtsonis"'
Autor:
Dimitra Gika, A. Zomas, A A Meletios Dimopoulos, Donna M. Weber, Marie C. Kyrtsonis, Gerassimos A. Pangalis, Athanasios Anagnostopoulos, Constantinos Zervas, N. Anagnostopoulos, Raymond Alexanian
Publikováno v:
Leukemia & Lymphoma. 45:2057-2061
Recent data have suggested that rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM). However, the patients that are more likely to benefit have not been clearly defined. In order to address this question we evaluate
Autor:
Marie C Kyrtsonis, Dimitra Gika, Konstantinos L. Bourantas, Meletios A. Dimopoulos, Athanasios Anagnostopoulos, Gerasimos A Pangalis, Argyris Symeonidis, Charis Matsouka, Konstantinos Zervas
Publikováno v:
Leukemia & Lymphoma. 45:1809-1813
Several studies have indicated that age, hemoglobin and serum albumin are among the most important prognostic factors for survival of patients with Waldenstrom's macroglobulinemia (WM). Furthermore, recent data indicate that serum b2-microglobulin ma
Autor:
Gerrassimos Pangalis, N. Anagnostopoulos, Constantinos Bourantas, Athanasios Anagnostopoulos, Constantinos Zervas, Marie C Kyrtsonis, Meletios A. Dimopoulos, Athanasios Zomas
Publikováno v:
Scopus-Elsevier
Rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia. However, many patients do not respond to this agent and several others develop secondary resistance. In order to identify clinical and laboratory parameters that could